01:30:10 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-01-10 Årsstämma 2024
2023-10-11 Bokslutskommuniké 2023
2023-07-07 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget är verksamma inom den skandinaviska marknaden. Newbury Pharmaceuticals har sitt huvudkontor i Lund.
2022-03-07 08:45:00

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lenalidomide Newbury in Sweden as the first country in a Scandinavian registration procedure. Approvals in Denmark and Norway are expected to follow upon finalized national reviews.

Lenalidomide is a prescription drug used to treat multiple myeloma and several other haematological malignancies. Lenalidomide is an immunomodulatory treatment and is taken as a capsule, once daily. The originator Revlimid is marketed in Sweden by Celgene – a BMS company and sales is estimated to be 1,4 billion SEK across Scandinavia in 2021 (source: DLMI Nordic Pharma Insights)

“We are pleased to see our portfolio of oncology products being approved by the Health Authorities. The approval of Lenalidomide Newbury is another regulatory milestone and we expect additional product approvals during the coming years”, says Lars Minor - CEO, Newbury Pharmaceuticals.

Lenalidomide Newbury is part of the oncology pipeline with 11 products expected to be registered in the years ahead. Oncology treatment costs are a big part of the total treatment costs for society and the future launch of Lenalidomide will support efficient use of resources and free-up reserves for new innovative products.